<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217474</url>
  </required_header>
  <id_info>
    <org_study_id>2017KYPJ052</org_study_id>
    <nct_id>NCT03217474</nct_id>
  </id_info>
  <brief_title>Femtosecond Laser-assisted Corneal Debridement for Herpes Simplex Keratitis</brief_title>
  <official_title>A Randomized Controlled Clinical Trial of Corneal Debridement for the Treatment of Herpes Simplex Epithelial Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chunxiao Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to learn if adding femtosecond laser-assisted corneal debridement
      to a standard therapy of oral ganciclovir can help shorten the healing time of herpes simplex
      epithelial keratitis (HSK).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing time</measure>
    <time_frame>14 ± 1 days</time_frame>
    <description>Time to complete corneal epithelial healing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal re-epithelization</measure>
    <time_frame>14 ± 1 days</time_frame>
    <description>Assessing complete corneal re-epithelization at day 14±1 using slit-lamp microcopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal opacity and vascularization</measure>
    <time_frame>Baseline, 14 ± 1 days, 3 months</time_frame>
    <description>Assessing corneal opacity and vascularization using slit-lamp microcopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>Baseline, 14 ± 1 days, 3 months</time_frame>
    <description>Assessing best-corrected visual acuity using ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal power and astigmatism</measure>
    <time_frame>Baseline, 14 ± 1 days, 3 months</time_frame>
    <description>Assessing changes of corneal power and astigmatism using autorefractor keratometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal sensation</measure>
    <time_frame>Baseline, 14 ± 1 days, 3 months</time_frame>
    <description>Assessing corneal sensation using Cochet-Bonnet esthesiometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>3 months</time_frame>
    <description>Assessing recurrent HSK using slit-lamp microcopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Herpes Simplex Keratitis</condition>
  <arm_group>
    <arm_group_label>FLDEB combined with GCV orally</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GCV orally</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ganciclovir (GCV) orally only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FLDEB</intervention_name>
    <description>The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.</description>
    <arm_group_label>FLDEB combined with GCV orally</arm_group_label>
    <other_name>Femtosecond laser-assisted corneal debridement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir (GCV)</intervention_name>
    <description>Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).</description>
    <arm_group_label>FLDEB combined with GCV orally</arm_group_label>
    <arm_group_label>GCV orally</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Femtosecond laser</intervention_name>
    <description>A commercial femtosecond laser to create a particular shaped graft for transplantation.</description>
    <arm_group_label>FLDEB combined with GCV orally</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged between 18 and 80 years old;

          2. Epithelial ulceration in a dendritic or geographic pattern, characteristic of
             infection with herpes simplex virus, and within 7 days of onset;

          3. Ulcer's stromal involvement &lt; 120 micron, as indicated by anterior segment optical
             coherence tomography;

          4. Informed consent signed by patient or legal guardian. Having the ability to comply
             with study assessments for the full duration of the study.

        Exclusion Criteria:

          1. Clinical signs of a cause other than herpes simplex virus for the epithelial
             keratitis;

          2. Antivirus or corticosteroid treatment within 6 months;

          3. Active stromal keratitis or iritis;

          4. History of allergy or adverse reaction to ganciclovir;

          5. High myopia with a spherical equivalent of -15.0 D or less;

          6. Corneal or ocular surface infection within 30 days prior to study entry;

          7. Ocular surface malignancy;

          8. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%;

          9. Renal failure with creatinine clearance&lt; 25ml/min;

         10. Alanine aminotransferase &gt; 40IU/L, or aspartate aminotransferase &gt; 40IU/L;

         11. Platelet levels &lt; 150,000 or &gt; 450,000 per microliter;

         12. Hemoglobin &lt; 12.0 g/dL (male) or &lt; 11.0 g/dL (female);

         13. Prothrombin time &gt; 16s and activated partial thrombin time &gt; 35s in patients not
             accepting anticoagulant therapy; An international normalized ratio greater than 3 in
             patients accepting anticoagulant therapy;

         14. Pregnancy (positive test) or lactation;

         15. Participation in another simultaneous medical investigation or clinical trial;

         16. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening;

         17. Severe dry eye disease as determined by Schirmer's test &lt; 2mm at least in one eye;

         18. Any medical or social condition that in the judgement of the investigator would
             interfere with or serve as a contraindication to adherence to the study protocol or
             ability to give informed consent;

         19. Active immunological diseases;

         20. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma
             filtering surgeries.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yizhi Liu, M.D.Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ting Huang, M.D.Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingfeng Zheng, M.D.Ph.D.</last_name>
    <phone>+8613922286455</phone>
    <email>yingfeng.zheng@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen Univerisity</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>5</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingfeng Zheng, M.D. Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Chunxiao Wang</investigator_full_name>
    <investigator_title>Clinical investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Keratitis</mesh_term>
    <mesh_term>Keratitis, Herpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

